BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Androxal enclomiphene: Phase II data

The single-blind, U.S. Phase II ZA-204 trial in 48 evaluable men with morning testosterone levels of <350 ng/dL showed that once-daily Androxal met the primary endpoint of significantly improving 24-hour average testosterone levels at week 6 compared to baseline. Specifically, 6.25, 12.5 and 25 mg doses of Androxal increased...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >